Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement
NCT ID: NCT00107900
Last Updated: 2019-02-26
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
606 participants
INTERVENTIONAL
2005-01-31
2005-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
NCT00398216
A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
NCT01203098
A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
NCT01181167
A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
NCT01203072
Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery
NCT01181141
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
15mg BID
15mg edoxaban administered twice daily (BID)
DU-176b
30mg QD
30mg edoxaban administered once daily (QD)
DU-176b
30mg BID
30mg edoxaban administered twice daily (BID)
DU-176b
60mg QD
60mg edoxaban administered once daily (QD)
DU-176b
60mg BID
60mg edoxaban administered twice daily (BID)
DU-176b
120mg QD
120mg edoxaban administered once daily (QD)
DU-176b
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DU-176b
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with increased risk of bleeding
* Uncontrolled hypertension (BP greater than 180/100 mmHg)
* Patients less than 111 lbs or more than 243 lbs
* Patients on long-term anticoagulants
* Patients with contraindications to venography
* Patients with medical history of venous thromboembolism
* Patients with impaired hepatic function
* Known to be pregnant
* Lactating women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daiichi Sankyo
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Daiichi Sankyo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
Decatur, Georgia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DU176b-PRT007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.